Breakthrough in Nanotechnology: Solid Lipid Nanoparticles for Ocular Therapeutics

Strategic Insights -

New research in the field of nanotechnology has shed light on the potential of solid lipid nanoparticles (SLNs) as innovative drug delivery systems for ocular applications. A systematic review, conducted by researchers at the University Institute of Pharmaceutical Sciences, has evaluated the ability of SLNs to improve bioavailability, sustain drug release, and overcome ocular barriers in treating anterior and posterior segment disorders such as dry eye syndrome, glaucoma, infections, and retinal diseases. The study highlights the advantages of SLNs, including enhanced corneal permeability, drug retention, and targeted delivery, making them a next-generation alternative to traditional delivery systems.

Key Takeaways:

  • The systematic review included 28 studies and 20 patents, covering SLNs encapsulating APIs such as econazole, atorvastatin, and cannabinoids.
  • Key findings highlighted enhanced bioavailability (up to 12-fold in vitreous humour for atorvastatin-SLNs), sustained release (24-96 h), and improved corneal permeability (up to 287% higher than controls).
  • Patented formulations incorporated cationic SLNs, PEGylated lipid nanoparticles, and bioactive-loaded SLNs, demonstrating superior stability and therapeutic efficacy.
  • No significant ocular toxicity was observed across in vitro and in vivo studies.
  • Challenges remain in industrial translation and regulatory hurdles, with recommendations for future research to focus on quality by design (QbD) formulation development and leveraging advanced characterization techniques.

Statistics:

  • Up to 28 studies and 20 patents met inclusion criteria for the systematic review.
  • Enhanced bioavailability was observed up to 12-fold in vitreous humour for atorvastatin-SLNs.
  • Sustained release was achieved for 24-96 h.
  • Improved corneal permeability was as high as 287% higher than controls.
  • No significant ocular toxicity was observed across in vitro and in vivo studies.

Sources:

  • Innovative solid lipid nanoparticle formulations for ocular therapeutics and related patents: A systematic review. Journal of Controlled Release, 2025:113992.
  • University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.
  • Nitika Saini, University Institute of Pharmaceutical Sciences.
  • Bakr Ahmed, Veluchamy A. Barathi, Vandana B. Patravale, Rohan M. Shah, and Indu Pal Kaur.
  • Journal of Controlled Release, Elsevier, Radarweg 29, 1043 NX Amsterdam, Netherlands.